Voyager Therapeutics and Neurocrine Biosciences to Collaborate on Parkinson’s Disease
- Posted by ISPE Boston
- On February 14, 2019
Cambridge-based Voyager Therapeutics and Neurocrine Biosciences and have announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs for Parkinson’s disease and Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience, drug development and commercialization with […]
Read More